Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Gene delivery appears safe for regenerating tooth-supporting gum tissue

Scientists at the University of Michigan have developed a method of gene delivery that appears safe for regenerating tooth-supporting gum tissue---a discovery that assuages one of the biggest safety concerns surrounding gene therapy research and tissue engineering.

8 Apr 2009

New tuberculosis vaccine effective in animal testing

A new tuberculosis vaccine candidate developed by researchers at Canada's McMaster University has proven effective in animal testing, the researchers announced Thursday, the Hamilton Spectator reports.

23 Mar 2009

New TB vaccine developed using a genetically modified adenovirus

McMaster University researchers are about to launch Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine totally designed, manufactured and tested within McMaster.

20 Mar 2009

Boosting its infectivity turns benign virus into good gene therapy carrier for cystic fibrosis

Researchers from the University of California, Berkeley, and the University of Iowa have turned a relatively benign virus into a highly infectious form that is ideal as a carrier for gene therapy.

16 Feb 2009

Gene-targeting approach for herpes treatment

A new therapy being developed at the University of Florida could, in time, produce another weapon for the fight against herpes.

3 Feb 2009

New vaccine developed for preventing human adenovirus type-3d virus

Common colds typically cause a week of sneezing, aches and pains and then fade away leaving only a sore nose and a few used sick days behind.

2 Feb 2009

Obesity may be contagious!

Professor Nikhil Dhurandhar says a common cold virus can interfere with our normal body processes and make us fat - he has reached this rather astonishing conclusion following ten years of research with both animals and humans into the virus, Adenovirus-36.

27 Jan 2009

New nasal spray vaccine shown to be effective against botulism

A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy .

8 Jan 2009

Chimerix completes phase I study and starts phase II multi-dose trial for CMX001

Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, has announced that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers.

6 Jan 2009

FDA to review Barr Pharmaceutical's BLA for adenovirus type 4 and 7 live oral vaccines

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review Duramed Pharmaceuticals, Inc.'s Adenovirus Types 4 and 7 Live Oral Vaccines Biologics License Application (BLA).

14 Dec 2008

Studies on imaging and tracking transplanted cells

Successfully monitoring the distribution and fate of transplanted stem cells through imaging and subsequent tracking would aid clinicians in their ability to evaluate the efficacy of transplanted cells.

10 Dec 2008

New vaccine principle delivers stronger and faster immune response

A new vaccine principle is being developed by scientists at the University of Copenhagen which - if it works to its full expected potential - could help to save millions of lives and revolutionise current vaccine technology.

24 Nov 2008

Analyses of Merck's HIV vaccine 'Step' study

Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online in two papers in The Lancet.

12 Nov 2008

Interferon eliminates specific causes of some viruses in heart failure patients, improving clinical outcomes

Giving interferon to heart failure patients with evidence of a chronic viral infection safely eliminated two viruses from their systems and reduced levels of a third virus.

11 Nov 2008

T-cell-based strategy for HIV-1 vaccines still viable option

The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.

10 Nov 2008

New findings on STEP HIV vaccine trial

The study is the result of the collaboration between scientists at the Institut de Genetique Moleculaire de Montpellier, Universite Montpellier I & II, Montpellier, France, the Centre Hospitalier Universitaire Vaudois (CHUV) and at the Swiss Vaccine Research Institute, University of Lausanne, Lausanne, Switzerland.

4 Nov 2008

Study shows how HIV-1 vaccine trial could have enhanced HIV infection

In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection.

4 Nov 2008

Transformation of ordinary cells into insulin-makers improves symptoms of diabetes

Scientists in the U.S. have successfully transformed ordinary cells into insulin-producing cells in a living mouse and thereby improved the symptoms of diabetes.

28 Aug 2008

Trial of new AIDS vaccine bites the dust

Plans to conduct a large-scale human trial of an experimental HIV/AIDS vaccine in the United States have bitten the dust.

21 Jul 2008

NIAID will not conduct the PAVE 100 HIV vaccine study

After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.

17 Jul 2008